Table 1.
Pathways | Factors | Model | Cells and Animals | Mechanisms | Effect | Reference |
---|---|---|---|---|---|---|
PRKN-dependent | IRI | CCCP for HK-2 cells and IRI for mice | PINK1 siRNA, PRKN siRNA, or double siRNA in cells; pink1-KO, prkn-KO or double-KO in mice. | 1. Reduce mitochondrial damage 2. Modulate the removal of ROS 3. Relieve inflammatory response 4. Modulate cell death |
Activation of mitophagy protects against AKI | [65] |
IRI | H/R for HK-2 cells and IRI for mice | PmirGLO-Dual-luciferase reporter vector of MEG3 and RTKN in cells; AAV-sh-MEG3 vector in mice via tail vein. |
Promoting apoptosis | Activation of mitophagy aggravates AKI | [66] | |
IRI | CCCP for RPTC cells and IRI for mice |
Pink1 shRNA in cells PT-atg7-KO in mice |
1.Suppressed mitochondrial depolarization 2.Improved ATP production 3.Inhibited the generation of ROS |
Activation of mitophagy protects against AKI | [72] | |
Sepsis | LPS for RPTC cells and LPS or CLP for mice | Pink1 siRNA, Prkn siRNA, or Optn siRNA in cells; pink1-KO or prkn KO in mice | 1. Mitochondrial quality control 2. Reduce cells apoptosis |
Activation of mitophagy protects against AKI | [81] | |
Sepsis | LPS for RPTC cells | Pink1 siRNA and Prkn siRNA in cells | 1. Inhibited the apoptosis 2. Remove damaged mitochondria |
Activation of mitophagy protects against AKI | [82] | |
Sepsis | LPS for HK-2 cells and CLP for rats | PRKN siRNA or SIRT1 inhibitor in HK-2 cells; Prkn silencing lentivirus and SIRT1 inhibitor EX527 in rats via tail vein | 1. Inhibited the apoptosis 2. Inhibited the pyroptosis 3. Remove damaged mitochondria |
Activation of mitophagy protects against AKI | [83] | |
Sepsis | CLP for mice | prkn-KO in mice | 1. Inhibition of mitochondrial dysfunction 2. Inhibition of NLRP3 inflammasome activation |
Activation of mitophagy protects against AKI | [84] | |
Cisplatin | Cisplatin injected intraperitoneally for mice | pink1-KO or prkn-KO in mice | Reduce cells apoptosis | Activation of mitophagy protects against AKI | [87] | |
Cisplatin | Cisplatin for RTECs and cisplatin injected intraperitoneally for mice | - | 1. Reversed cellular ROS induced by cisplatin 2. Reversed mitochondrial membrane potential level induced by cisplatin |
Activation of mitophagy protects against AKI | [88] | |
Cisplatin | Cisplatin for HK-2 | PINK1 siRNA, PRKN siRNA and PINK1 or PRKN overexpression plasmids in HK-2 | 1. Protected against mitochondrial dysfunction 2. Protected against cell injury |
Activation of mitophagy protects against AKI | [89] | |
Cisplatin | Intraperitoneal injection of cisplatin for rats | pink1-KO in rats | 1. PINK1 deficiency inhibited DNM1L-mediated mitochondrial fission 2. PINK1 deficiency inhibited excessive mitophagy |
Excessive mitophagy aggravates AKI | [90] | |
Contrast | Iohexol for HK-2 and iohexol administration for mice | PINK1 siRNA or PRKN siRNA in cells; pink1-KO or prkn-KO in mice | 1. Reduce mitochondrial ROS 2. Reduce NLRP3 inflammasome activation |
Activation of mitophagy protects against AKI | [91] | |
Contrast | Ioversol for HK-2 and ioversol for rats | - | 1. Reduce oxidative stress 2. Reduce mitochondrial damage |
Activation of mitophagy protects against AKI | [94] | |
PRKN-independent | IRI | OGD-R for BUMPT cells and IRI for mice | Bnip3 silence in cells; bnip3-KO in mice | 1. Eliminate damaged mitochondria 2. Modulate the removal of ROS 3. Modulate cell death 4. Relieve inflammatory response |
Activation of mitophagy protects against AKI | [64] |
IRI | IRI for rats | Mdivi-1, an inhibitor of DNM1L, in rats | 1. Mitophagic clearance of damaged mitochondria 2. Protects cells apoptosis. |
Activation of mitophagy protects against AKI | [73] | |
IRI | IRI for mice | cnp-KO in mice. | Aggressive removal of injured mitochondria | Activation of mitophagy protects against AKI | [74] | |
IRI | H/R for HK-2 cells and IRI for mice | HIF1A siRNA, BNIP3 siRNA, and BNIP3-overexpression plasmid for cell; hif1a-CKO and bnip3-overexpression adenovirus in mice | 1. Inhibited apoptosis 2. Inhibited ROS production |
Activation of mitophagy protects against AKI | [75] | |
IRI | IRI for mice and rotenone for primary tubule cells | fundc1-PTKO, dnm1l-PTKO, ulk1-PTKO and fundc1-dnm1l-PTKO in mice | 1. Mitochondrial quality control 2. Reduce ROS oxidative stress 3. Reduce mitochondrial apoptosis |
Activation of mitophagy protects against AKI | [76] | |
Contrast | Iohexol for HK-2 and iohexol administration for mice | BNIP3 siRNA in cells; bnip3-KO in mice | Reduce cells apoptosis | Activation of mitophagy protects against AKI | [93] |